法莫替丁 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "法莫替丁" in Chinese language version.

refsWebsite

Global rank Chinese rank

20doi.org

2^nd place

23^rd place

15web.archive.org

1^st place

15nih.gov

4^th place

5^th place

4fda.gov

447^th place

581^st place

3sciencedirect.com

149^th place

292^nd place

3archive.org

6^th place

4^th place

2springer.com

274^th place

320^th place

2mayoclinic.org

1,610^th place

2,275^th place

1wiley.com

222^nd place

216^th place

1books.google.com

3^rd place

8^th place

1espacenet.com

800^th place

1,214^th place

1uspto.gov

1,459^th place

1,685^th place

1pat2pdf.org

low place

1skyscape.com

low place

1elsevier.com

610^th place

388^th place

1worldcat.org

5^th place

12^th place

1medicines.org.uk

3,823^rd place

3,456^th place

1farmavita.net

low place

1semanticscholar.org

11^th place

332^nd place

1proquest.com

206^th place

2,065^th place

1psychopharmacologyinstitute.com

low place

1journalofinfection.com

low place

1wikipedia.org

low place

1drugs.com

399^th place

208^th place

1rxlist.com

7,927^th place

5,088^th place

archive.org

Borody, TJ; Andrews, P; Fracchia, G; Brandl, S; Shortis, NP; Bae, H. Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori.. Gut. October 1995, 37 (4): 477–81. PMC 1382896 . PMID 7489931. doi:10.1136/gut.37.4.477.
Escolano, F; Castaño, J; López, R; Bisbe, E; Alcón, A. Effects of omeprazole, ranitidine, famotidine and placebo on gastric secretion in patients undergoing elective surgery.. British journal of anaesthesia. October 1992, 69 (4): 404–6. PMID 1419452. doi:10.1093/bja/69.4.404.
Vila, P; Vallès, J; Canet, J; Melero, A; Vidal, F. Acid aspiration prophylaxis in morbidly obese patients: famotidine vs. ranitidine.. Anaesthesia. November 1991, 46 (11): 967–9. PMID 1750602. doi:10.1111/j.1365-2044.1991.tb09860.x.

books.google.com

Fischer, Janos. Analogue-based Drug Discovery II. John Wiley & Sons. 2010: 4 [2018-09-11]. ISBN 978-3-527-63212-1. （原始内容存档于2020-07-29）.

doi.org

Humphries TJ, Merritt GJ. Review article: drug interactions with agents used to treat acid-related diseases (pdf). Aliment. Pharmacol. Ther. August 1999, 13 (Suppl 3): 18–26 [2015-09-27]. PMID 10491725. doi:10.1046/j.1365-2036.1999.00021.x. （原始内容存档于2015-12-03）.
J.M. Howard, A.N. Chremos, M.J. Collen, K.E. Mcarthur, J.A. Cherner, P.N. Maton, C.A. Ciarleglio, M.J. Cornelius, J.D. Gardner, R.T. Jensen. Famotidine, a New, Potent, Long-Acting Histamine H2-Receptor Antagonist: Comparison With Cimetidine and Ranitidine in the Treatment of Zollinger-Ellison Syndrome. Gastroenterology. 1985-04, 88 (4): 1026–1033 [2018-09-11]. ISSN 0016-5085. doi:10.1016/s0016-5085(85)80024-x. （原始内容存档于2019-08-20）.
Ronnita C. Sequeira, Angel Godad. Novel insights into famotidine as a GSK-3β inhibitor: An explorative study in aluminium chloride-induced Alzheimer’s disease rat model. Behavioural Brain Research. 2024-05-16, 476 [2024-09-20]. doi:10.1016/j.bbr.2024.115270.
Mohammad M, Al-Masri IM, Issa A, Al-Ghussein MA, Fararjeh M, Alkhatib H, et al. Famotidine inhibits glycogen synthase kinase-3β: an investigation by docking simulation and experimental validation. Journal of Enzyme Inhibition and Medicinal Chemistry. August 2013, 28 (4): 690–694. PMID 22512725. S2CID 11890710. doi:10.3109/14756366.2012.672413 .
Meskanen, K; Ekelund, H; Laitinen, J; Neuvonen, PJ; Haukka, J; Panula, P; Ekelund, J. A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia.. Journal of Clinical Psychopharmacology. August 2013, 33 (4): 472–478. PMID 23764683. doi:10.1097/JCP.0b013e3182970490.
Areej Turkistani, Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Ali K. Albuhadily, Athanasios Alexiou, Marios Papadakis, Mohamed M. Elfiky, Hebatallah M. Saad & Gaber El-Saber Batiha. Therapeutic Potential Effect of Glycogen Synthase Kinase 3 Beta (GSK-3β) Inhibitors in Parkinson Disease: Exploring an Overlooked Avenue. Molecular Neurobiology. 2024-02-17, 61: 7092–7108 [2024-01-20]. doi:10.1007/s12035-024-04003-z.
Gokhan Unal, Alim Hüseyin Dokumaci, Ceren Sahin Ozkartal, Mukerrem Betul Yerer, Feyza Aricioglu. Famotidine has a neuroprotective effect on MK-801 induced toxicity via the Akt/GSK-3β/β-catenin signaling pathway in the SH-SY5Y cell line. Chemico-Biological Interactions. 2019-12-01, 314. doi:10.1016/j.cbi.2019.108823.
Gokhan Unal, Feyza Aricioglu. Famotidine Improved Schizophrenia-Like Behaviors in Acute Ketamine Model of Schizophrenia in Rats 10 (2): 45–54. 2020-03-30 [2020-05-06]. doi:10.5455/PBS.20200330095749.
Huzaifa Ahmad Cheema, Arman Shafiee, Mohammad Mobin Teymouri Athar, Abia Shahid, Rehmat Ullah Awan, Ahmed M Afifi, Jaffer Shah, Prasun K Jalal. No evidence of clinical efficacy of famotidine for the treatment of COVID-19: a systematic review and meta-analysis. Infection. 2022-11-30, 86: 154–225 [2022-11-24]. doi:10.1016/j.jinf.2022.11.022.
L.A.Linday, J.A.Tsiouris, I.L.Cohen, R.Shindledecker, R.DeCresce. Famotidine treatment of children with autistic spectrum disorders: pilot research using single subject research design 108: 593–611. 2000-08-14 [2000-11-01]. doi:10.1007/s007020170059.
L.A. Linday. Oral famotidine: a potential treatment for children with autism. Medical Hypotheses. 1997-05, 48 (5): 381–386. doi:10.1016/S0306-9877(97)90032-3.
Soga, T; Matsuura, M; Kodama, Y; Fujita, T; Sekimoto, I; Nishimura, K; Yoshida, S; Kutsumi, H; Fujimoto, S. Is a proton pump inhibitor necessary for the treatment of lower-grade reflux esophagitis?. Journal of gastroenterology. August 1999, 34 (4): 435–40. PMID 10452673. doi:10.1007/s005350050292.
Borody, TJ; Andrews, P; Fracchia, G; Brandl, S; Shortis, NP; Bae, H. Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori.. Gut. October 1995, 37 (4): 477–81. PMC 1382896 . PMID 7489931. doi:10.1136/gut.37.4.477.
Hu, FL; Jia, JC; Li, YL; Yang, GB. Comparison of H2-receptor antagonist- and proton-pump inhibitor-based triple regimens for the eradication of Helicobacter pylori in Chinese patients with gastritis or peptic ulcer.. The Journal of international medical research. 2003, 31 (6): 469–74. PMID 14708410. doi:10.1177/147323000303100601.
Fujiwara, Y; Higuchi, K; Nebiki, H; Chono, S; Uno, H; Kitada, K; Satoh, H; Nakagawa, K; Kobayashi, K. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.. Alimentary Pharmacology & Therapeutics. June 2005,. 21 Suppl 2: 10–8. PMID 15943841. doi:10.1111/j.1365-2036.2005.02468.x.
La Corte, R; Caselli, M; Castellino, G; Bajocchi, G; Trotta, F. Prophylaxis and treatment of NSAID-induced gastroduodenal disorders.. Drug safety. June 1999, 20 (6): 527–43. PMID 10392669. doi:10.2165/00002018-199920060-00006.
Laine, L; Kivitz, AJ; Bello, AE; Grahn, AY; Schiff, MH; Taha, AS. Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers.. The American Journal of Gastroenterology. March 2012, 107 (3): 379–86. PMC 3321505 . PMID 22186979. doi:10.1038/ajg.2011.443.
Escolano, F; Castaño, J; López, R; Bisbe, E; Alcón, A. Effects of omeprazole, ranitidine, famotidine and placebo on gastric secretion in patients undergoing elective surgery.. British journal of anaesthesia. October 1992, 69 (4): 404–6. PMID 1419452. doi:10.1093/bja/69.4.404.
Vila, P; Vallès, J; Canet, J; Melero, A; Vidal, F. Acid aspiration prophylaxis in morbidly obese patients: famotidine vs. ranitidine.. Anaesthesia. November 1991, 46 (11): 967–9. PMID 1750602. doi:10.1111/j.1365-2044.1991.tb09860.x.
Jahr, JS; Burckart, G; Smith, SS; Shapiro, J; Cook, DR. Effects of famotidine on gastric pH and residual volume in pediatric surgery.. Acta anaesthesiologica Scandinavica. July 1991, 35 (5): 457–60. PMID 1887750. doi:10.1111/j.1399-6576.1991.tb03328.x.

drugs.com

Drugs.com duexis （页面存档备份，存于互联网档案馆）

elsevier.com

linkinghub.elsevier.com

J.M. Howard, A.N. Chremos, M.J. Collen, K.E. Mcarthur, J.A. Cherner, P.N. Maton, C.A. Ciarleglio, M.J. Cornelius, J.D. Gardner, R.T. Jensen. Famotidine, a New, Potent, Long-Acting Histamine H2-Receptor Antagonist: Comparison With Cimetidine and Ranitidine in the Treatment of Zollinger-Ellison Syndrome. Gastroenterology. 1985-04, 88 (4): 1026–1033 [2018-09-11]. ISSN 0016-5085. doi:10.1016/s0016-5085(85)80024-x. （原始内容存档于2019-08-20）.

espacenet.com

worldwide.espacenet.com

US patent 4283408, Yasufumi Hirata, Isao Yanagisawa, Yoshio Ishii, Shinichi Tsukamoto, Noriki Ito, Yasuo Isomura and Masaaki Takeda, "Guanidinothiazole compounds, process for preparation and gastric inhibiting compositions containing them", issued 11 August 1981美国专利4283408 (PDF 版本)（于1981年08月11日注册）Yasufumi Hirata, Isao Yanagisawa, Yoshio Ishii, Shinichi Tsukamoto, Noriki Ito, Yasuo Isomura and Masaaki Takeda——Guanidinothiazole compounds, process for preparation and gastric inhibiting compositions containing them。

farmavita.net

Formulation and Evaluation of Gastroretentive Floating Tablets of Famotidine. Farmavita.Net. 2008 [2009-01-31]. （原始内容存档于2016-03-29）.

fda.gov

accessdata.fda.gov

Drugs@FDA: Pepcid. [2018-09-11]. （原始内容存档于2021-03-21）.
Drug Approval Package: Pecid RPD (Famotidine) NDA# 020752. [2018-09-11]. （原始内容存档于2021-03-31）.
Drugs@FDA: Fluxid. [2018-09-11].
Drugs@FDA: Pepcid Complete. [2018-09-13]. （原始内容存档于2021-03-22）.

journalofinfection.com

Huzaifa Ahmad Cheema, Arman Shafiee, Mohammad Mobin Teymouri Athar, Abia Shahid, Rehmat Ullah Awan, Ahmed M Afifi, Jaffer Shah, Prasun K Jalal. No evidence of clinical efficacy of famotidine for the treatment of COVID-19: a systematic review and meta-analysis. Infection. 2022-11-30, 86: 154–225 [2022-11-24]. doi:10.1016/j.jinf.2022.11.022.

mayoclinic.org

Zollinger-Ellison syndrome - Diagnosis and treatment - Mayo Clinic. www.mayoclinic.org. [2018-09-11]. （原始内容存档于2020-09-18）（英语）.
Esophagitis - Diagnosis and treatment - Mayo Clinic. www.mayoclinic.org. [2018-09-11]. （原始内容存档于2021-01-21）（英语）.

medicines.org.uk

PepcidTwo Chewable. [2015-06-07]. （原始内容存档于2016-07-18）.

nih.gov

ncbi.nlm.nih.gov

Humphries TJ, Merritt GJ. Review article: drug interactions with agents used to treat acid-related diseases (pdf). Aliment. Pharmacol. Ther. August 1999, 13 (Suppl 3): 18–26 [2015-09-27]. PMID 10491725. doi:10.1046/j.1365-2036.1999.00021.x. （原始内容存档于2015-12-03）.
Mohammad M, Al-Masri IM, Issa A, Al-Ghussein MA, Fararjeh M, Alkhatib H, et al. Famotidine inhibits glycogen synthase kinase-3β: an investigation by docking simulation and experimental validation. Journal of Enzyme Inhibition and Medicinal Chemistry. August 2013, 28 (4): 690–694. PMID 22512725. S2CID 11890710. doi:10.3109/14756366.2012.672413 .
Meskanen, K; Ekelund, H; Laitinen, J; Neuvonen, PJ; Haukka, J; Panula, P; Ekelund, J. A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia.. Journal of Clinical Psychopharmacology. August 2013, 33 (4): 472–478. PMID 23764683. doi:10.1097/JCP.0b013e3182970490.
Kanayama, S. Proton-pump inhibitors versus H2-receptor antagonists in triple therapy for Helicobacter pylori eradication. Nihon rinsho. Japanese journal of clinical medicine. January 1999, 57 (1): 153–6. PMID 10036954.
Soga, T; Matsuura, M; Kodama, Y; Fujita, T; Sekimoto, I; Nishimura, K; Yoshida, S; Kutsumi, H; Fujimoto, S. Is a proton pump inhibitor necessary for the treatment of lower-grade reflux esophagitis?. Journal of gastroenterology. August 1999, 34 (4): 435–40. PMID 10452673. doi:10.1007/s005350050292.
Borody, TJ; Andrews, P; Fracchia, G; Brandl, S; Shortis, NP; Bae, H. Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori.. Gut. October 1995, 37 (4): 477–81. PMC 1382896 . PMID 7489931. doi:10.1136/gut.37.4.477.
Hu, FL; Jia, JC; Li, YL; Yang, GB. Comparison of H2-receptor antagonist- and proton-pump inhibitor-based triple regimens for the eradication of Helicobacter pylori in Chinese patients with gastritis or peptic ulcer.. The Journal of international medical research. 2003, 31 (6): 469–74. PMID 14708410. doi:10.1177/147323000303100601.
Kirika, NV; Bodrug, NI; Butorov, IV; Butorov, SI. [Efficacy of different schemes of anti-helicobacter therapy in duodenal ulcer].. Terapevticheskii arkhiv. 2004, 76 (2): 18–22. PMID 15106408.
Fujiwara, Y; Higuchi, K; Nebiki, H; Chono, S; Uno, H; Kitada, K; Satoh, H; Nakagawa, K; Kobayashi, K. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.. Alimentary Pharmacology & Therapeutics. June 2005,. 21 Suppl 2: 10–8. PMID 15943841. doi:10.1111/j.1365-2036.2005.02468.x.
La Corte, R; Caselli, M; Castellino, G; Bajocchi, G; Trotta, F. Prophylaxis and treatment of NSAID-induced gastroduodenal disorders.. Drug safety. June 1999, 20 (6): 527–43. PMID 10392669. doi:10.2165/00002018-199920060-00006.
Laine, L; Kivitz, AJ; Bello, AE; Grahn, AY; Schiff, MH; Taha, AS. Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers.. The American Journal of Gastroenterology. March 2012, 107 (3): 379–86. PMC 3321505 . PMID 22186979. doi:10.1038/ajg.2011.443.
Escolano, F; Castaño, J; López, R; Bisbe, E; Alcón, A. Effects of omeprazole, ranitidine, famotidine and placebo on gastric secretion in patients undergoing elective surgery.. British journal of anaesthesia. October 1992, 69 (4): 404–6. PMID 1419452. doi:10.1093/bja/69.4.404.
Vila, P; Vallès, J; Canet, J; Melero, A; Vidal, F. Acid aspiration prophylaxis in morbidly obese patients: famotidine vs. ranitidine.. Anaesthesia. November 1991, 46 (11): 967–9. PMID 1750602. doi:10.1111/j.1365-2044.1991.tb09860.x.
Jahr, JS; Burckart, G; Smith, SS; Shapiro, J; Cook, DR. Effects of famotidine on gastric pH and residual volume in pediatric surgery.. Acta anaesthesiologica Scandinavica. July 1991, 35 (5): 457–60. PMID 1887750. doi:10.1111/j.1399-6576.1991.tb03328.x.

nlm.nih.gov

Famotidine. [2018-09-11]. （原始内容存档于2016-07-05）.

pat2pdf.org

US patent 4283408, Yasufumi Hirata, Isao Yanagisawa, Yoshio Ishii, Shinichi Tsukamoto, Noriki Ito, Yasuo Isomura and Masaaki Takeda, "Guanidinothiazole compounds, process for preparation and gastric inhibiting compositions containing them", issued 11 August 1981美国专利4283408 (PDF 版本)（于1981年08月11日注册）Yasufumi Hirata, Isao Yanagisawa, Yoshio Ishii, Shinichi Tsukamoto, Noriki Ito, Yasuo Isomura and Masaaki Takeda——Guanidinothiazole compounds, process for preparation and gastric inhibiting compositions containing them。

proquest.com

Gokhan Unal, Feyza Aricioglu. Famotidine Improved Schizophrenia-Like Behaviors in Acute Ketamine Model of Schizophrenia in Rats 10 (2): 45–54. 2020-03-30 [2020-05-06]. doi:10.5455/PBS.20200330095749.

psychopharmacologyinstitute.com

Famotidine for COVID-19 Brain Fog: A Promising Treatment Option. [2024-05-01] （英语）.

rxlist.com

Pepcid Side Effects & Drug Interactions. RxList.com. 2008 [2008-07-31]. （原始内容存档于2008-09-06）.

sciencedirect.com

Ronnita C. Sequeira, Angel Godad. Novel insights into famotidine as a GSK-3β inhibitor: An explorative study in aluminium chloride-induced Alzheimer’s disease rat model. Behavioural Brain Research. 2024-05-16, 476 [2024-09-20]. doi:10.1016/j.bbr.2024.115270.
Gokhan Unal, Alim Hüseyin Dokumaci, Ceren Sahin Ozkartal, Mukerrem Betul Yerer, Feyza Aricioglu. Famotidine has a neuroprotective effect on MK-801 induced toxicity via the Akt/GSK-3β/β-catenin signaling pathway in the SH-SY5Y cell line. Chemico-Biological Interactions. 2019-12-01, 314. doi:10.1016/j.cbi.2019.108823.
L.A. Linday. Oral famotidine: a potential treatment for children with autism. Medical Hypotheses. 1997-05, 48 (5): 381–386. doi:10.1016/S0306-9877(97)90032-3.

semanticscholar.org

api.semanticscholar.org

Mohammad M, Al-Masri IM, Issa A, Al-Ghussein MA, Fararjeh M, Alkhatib H, et al. Famotidine inhibits glycogen synthase kinase-3β: an investigation by docking simulation and experimental validation. Journal of Enzyme Inhibition and Medicinal Chemistry. August 2013, 28 (4): 690–694. PMID 22512725. S2CID 11890710. doi:10.3109/14756366.2012.672413 .

skyscape.com

mediwire.skyscape.com

Sankyo Pharma. Skyscape Mediwire. 2002 [2009-10-31]. （原始内容存档于2009-02-23）.

springer.com

link.springer.com

Areej Turkistani, Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Ali K. Albuhadily, Athanasios Alexiou, Marios Papadakis, Mohamed M. Elfiky, Hebatallah M. Saad & Gaber El-Saber Batiha. Therapeutic Potential Effect of Glycogen Synthase Kinase 3 Beta (GSK-3β) Inhibitors in Parkinson Disease: Exploring an Overlooked Avenue. Molecular Neurobiology. 2024-02-17, 61: 7092–7108 [2024-01-20]. doi:10.1007/s12035-024-04003-z.
L.A.Linday, J.A.Tsiouris, I.L.Cohen, R.Shindledecker, R.DeCresce. Famotidine treatment of children with autistic spectrum disorders: pilot research using single subject research design 108: 593–611. 2000-08-14 [2000-11-01]. doi:10.1007/s007020170059.

uspto.gov

patft.uspto.gov

US patent 4283408, Yasufumi Hirata, Isao Yanagisawa, Yoshio Ishii, Shinichi Tsukamoto, Noriki Ito, Yasuo Isomura and Masaaki Takeda, "Guanidinothiazole compounds, process for preparation and gastric inhibiting compositions containing them", issued 11 August 1981美国专利4283408 (PDF 版本)（于1981年08月11日注册）Yasufumi Hirata, Isao Yanagisawa, Yoshio Ishii, Shinichi Tsukamoto, Noriki Ito, Yasuo Isomura and Masaaki Takeda——Guanidinothiazole compounds, process for preparation and gastric inhibiting compositions containing them。

web.archive.org

Humphries TJ, Merritt GJ. Review article: drug interactions with agents used to treat acid-related diseases (pdf). Aliment. Pharmacol. Ther. August 1999, 13 (Suppl 3): 18–26 [2015-09-27]. PMID 10491725. doi:10.1046/j.1365-2036.1999.00021.x. （原始内容存档于2015-12-03）.
Fischer, Janos. Analogue-based Drug Discovery II. John Wiley & Sons. 2010: 4 [2018-09-11]. ISBN 978-3-527-63212-1. （原始内容存档于2020-07-29）.
Sankyo Pharma. Skyscape Mediwire. 2002 [2009-10-31]. （原始内容存档于2009-02-23）.
J.M. Howard, A.N. Chremos, M.J. Collen, K.E. Mcarthur, J.A. Cherner, P.N. Maton, C.A. Ciarleglio, M.J. Cornelius, J.D. Gardner, R.T. Jensen. Famotidine, a New, Potent, Long-Acting Histamine H2-Receptor Antagonist: Comparison With Cimetidine and Ranitidine in the Treatment of Zollinger-Ellison Syndrome. Gastroenterology. 1985-04, 88 (4): 1026–1033 [2018-09-11]. ISSN 0016-5085. doi:10.1016/s0016-5085(85)80024-x. （原始内容存档于2019-08-20）.
Drugs@FDA: Pepcid. [2018-09-11]. （原始内容存档于2021-03-21）.
Drug Approval Package: Pecid RPD (Famotidine) NDA# 020752. [2018-09-11]. （原始内容存档于2021-03-31）.
Drugs@FDA: Pepcid Complete. [2018-09-13]. （原始内容存档于2021-03-22）.
PepcidTwo Chewable. [2015-06-07]. （原始内容存档于2016-07-18）.
Formulation and Evaluation of Gastroretentive Floating Tablets of Famotidine. Farmavita.Net. 2008 [2009-01-31]. （原始内容存档于2016-03-29）.
Australian Medicines Handbook （页面存档备份，存于互联网档案馆），2005. Adelaide: Australian Medicines Handbook. ISBN 0-9578521-9-3。
Zollinger-Ellison syndrome - Diagnosis and treatment - Mayo Clinic. www.mayoclinic.org. [2018-09-11]. （原始内容存档于2020-09-18）（英语）.
Esophagitis - Diagnosis and treatment - Mayo Clinic. www.mayoclinic.org. [2018-09-11]. （原始内容存档于2021-01-21）（英语）.
Famotidine. [2018-09-11]. （原始内容存档于2016-07-05）.
Drugs.com duexis （页面存档备份，存于互联网档案馆）
Pepcid Side Effects & Drug Interactions. RxList.com. 2008 [2008-07-31]. （原始内容存档于2008-09-06）.

wikipedia.org

en.wikipedia.org

Australian Medicines Handbook （页面存档备份，存于互联网档案馆），2005. Adelaide: Australian Medicines Handbook. ISBN 0-9578521-9-3。

wiley.com

onlinelibrary.wiley.com

Humphries TJ, Merritt GJ. Review article: drug interactions with agents used to treat acid-related diseases (pdf). Aliment. Pharmacol. Ther. August 1999, 13 (Suppl 3): 18–26 [2015-09-27]. PMID 10491725. doi:10.1046/j.1365-2036.1999.00021.x. （原始内容存档于2015-12-03）.

worldcat.org

J.M. Howard, A.N. Chremos, M.J. Collen, K.E. Mcarthur, J.A. Cherner, P.N. Maton, C.A. Ciarleglio, M.J. Cornelius, J.D. Gardner, R.T. Jensen. Famotidine, a New, Potent, Long-Acting Histamine H2-Receptor Antagonist: Comparison With Cimetidine and Ranitidine in the Treatment of Zollinger-Ellison Syndrome. Gastroenterology. 1985-04, 88 (4): 1026–1033 [2018-09-11]. ISSN 0016-5085. doi:10.1016/s0016-5085(85)80024-x. （原始内容存档于2019-08-20）.